Clinical Trials Directory

Trials / Completed

CompletedNCT03058978

Assessing Ovarian Function During Prolonged Implant Use

Status
Completed
Phase
Study type
Observational
Enrollment
117 (actual)
Sponsor
Planned Parenthood of the St. Louis Region and Southwest Missouri · Academic / Other
Sex
Female
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The study will evaluate how the ovaries may be functioning while using the the Implanon®/Nexplanon® during the three years beyond the FDA approved duration. Ovarian function will be assessed with weekly serum progesterone levels. Participants will undergo weekly venipuncture for a total of four draws. Participants will be followed for 30 days.

Detailed description

This prospective cohort will evaluate the ovarian function of 210 ENG users during the three years beyond the FDA approved duration. Participants enrolled in the current study, EPIC (Evaluating the Prolonged Use of IUD and Implant for Contraception, NCT02267616), will be contacted via telephone, screened and scheduled to enroll in person. After the signed consent is obtained participants will be asked to complete a brief questionnaire on demographic information and bleeding patterns. Participants will undergo a blood draw to assess serum etonogestrel and serum progesterone levels. Follow up visits will include a weekly blood draw for three weeks to assess serum progesterone levels. Participants will also complete a bleeding diary to assess daily bleeding patterns for the 30 day study period. The investigators will enroll participants at seven time points; at method expiration (3 years of use), and in six-month intervals through six years of use.

Conditions

Interventions

TypeNameDescription
DEVICEEtonogestrel ImplantOvarian function will be assessed with weekly serum progesterone levels. Participants will undergo weekly venipuncture for a total of four draws over a 30 day period. Participants will also complete a bleeding diary to assess daily bleeding patterns for the 30 day study period.

Timeline

Start date
2017-03-01
Primary completion
2021-12-30
Completion
2021-12-30
First posted
2017-02-23
Last updated
2022-07-12

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT03058978. Inclusion in this directory is not an endorsement.